Thrombosis Cardiac Clinical Trial
Official title:
De Novo Cerebral Microembolization Associated With Patent Foramen Ovale Closure
This study aims to investigate (1) the de novo cerebral microembolization in patients who undergo transcatheter closure of PFO or ASD, and (2) evaluate the relationship between de novo cerebral microembolization and in situ thrombus within PFO.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | PFO group Inclusion Criteria: 1) age 18 to 65 years; 2) documented PFO with medium-to-large shunts (= 20 microbubbles by c-TCD at rest or during the Valsalva maneuver); 3) history of embolic stroke (based on brain magnetic resonance imaging within 24 hours after symptom onset) or TIA within 6 months without other identifiable causes; 4) history of migraine for more than one year without other identifiable causes; 5) asymptomatic group: incidental finding of PFO in asymptomatic individuals, and presence of high-risk activities and/or anatomical features related to PFO (high-risk activities were defined as those in which the Valsalva maneuver was performed frequently or those that increased the risk of venous gas formation; and high-risk anatomical features included atrial septal aneurysm and/or curtain pattern on c-TCD). Exclusion Criteria: 1) presence of any known vascular risk factor, including hypertension, hypercholesterolemia, diabetes mellitus, atrial fibrillation, smoking and obesity; 2) history of embolic stroke or TIA within the past one month; 3) history of deep vein thrombosis or pulmonary embolism; 4) presence of coronary artery disease and carotid artery lesions; 5) presence of coexistent cardiovascular structural malformations or diseases; 6) allergy to contrast medium; 7) refusal to participate. ASD group Inclusion Criteria: 1) age 18 to 65 years; 2) secundum ASD size 10 to 20 mm, with sufficient surrounding rims, except the aortic rim; 3) right heart catheterization: resting SPAP < 50 mm Hg, Qp/Qs = 1.5 and PVR < 5 WU. Exclusion Criteria: 1) presence of any known vascular risk factor, including hypertension, hypercholesterolemia, diabetes mellitus, atrial fibrillation, smoking and obesity; 2) associated with other cardiac abnormalities or diseases; 3) resting SPAP =50 mm Hg and resting PVR =5 Wood units;4) primum or sinus venosus type ASD; 5) presence of intracardiac thrombi, permanent contraindications to platelet therapy, and allergic reaction to nickel. |
Country | Name | City | State |
---|---|---|---|
China | Chaowu Yan | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
China National Center for Cardiovascular Diseases |
China,
Yan C, Li H, Wang C, Yu H, Guo T, Wan L, Yundan P, Wang L, Fang W. Frequency and Size of In Situ Thrombus Within Patent Foramen Ovale. Stroke. 2023 May;54(5):1205-1213. doi: 10.1161/STROKEAHA.122.041524. Epub 2023 Mar 9. — View Citation
Yan C, Li H. Preliminary Investigation of In situ Thrombus Within Patent Foramen Ovale in Patients With and Without Stroke. JAMA. 2021 May 25;325(20):2116-2118. doi: 10.1001/jama.2021.4359. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | De novo cerebral microembolization | cerebral microembolization with diffusion-weighted magnetic resonance imaging | 24 hours to 4 weeks after closure of PFO/ASD |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04073875 -
18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis
|
||
Recruiting |
NCT04649034 -
Intraventricular Stasis In Cardiovascular Disease
|
||
Completed |
NCT03795883 -
The Thrombotic Potential of Heart Chambers in the Presence or Absence of Atrial Fibrillation.
|
||
Not yet recruiting |
NCT06327659 -
Efficacy of Using 50 ml Syringe Manual Thrombectomy Catheter in Primary PCI With Heavy Thrombus Burden
|
Phase 3 |